

COLLINS

UNITED STATE PARTMENT OF COMMERCE Patent and Tra Phark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NUMBER FILING DATE FIRST NAMED APPLICANT

09/011,745

ATTORNEY DOCKET NO.

06/22/98

EXAMINER

.HM12/0830

PATRICK J HAGAN DANN DORFMAN HERRELL & SKILLMAN 1601 MARKET STREET SUITE 720 PHILADELPHIA PA 19103-2307

ART UNITIZO D PAPER NUMBER

DATE MAILEO:36

08/30/99

This is a communication from the examiner in charge of your application. COMMISSIONER OF PATENTS AND TRADEMARKS

NOTICE OF ALLOWABILITY

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed); a Notice of Allowance and Issue Fee Due or other appropriate communication will be mailed in due course.
This communication is responsive to the Amendment filed 6/17/99
The allowed claim(s) is/are 1-3 and 30-61
☐ The drawings filed on are acceptable.
Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
☑ All ☐ Some* ☐ None of the CERTIFIED copies of the priority documents have been
☐ received.
received in Application No. (Series Code/Serial Number)
Preceived in this national stage application from the International Bureau (PCT Rule 17.2(a)).
*Certified copies not received:
Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).
A SHORTENED STATUTORY PERIOD FOR RESPONSE to comply with the requirements noted below is set to EXPIRE THREE MONTHS FROM THE "DATE MAILED" of this Office action. Failure to timely comply will result in ABANDONMENT of this application. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).
Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL APPLICATION, PTO-152, which discloses that the oath or declaration is deficient. A SUBSTITUTE OATH OR DECLARATION IS REQUIRED.
Applicant MUST submit NEW FORMAL DRAWINGS
because the originally filed drawings were declared by applicant to be informal.
including changes required by the Notice of Draftperson's Patent Drawing Review, PTO-948, attached hereto or to Paper No
including changes required by the proposed drawing correction filed on, which has been approved by the examiner.
including changes required by the proposed drawing correction filed on which has been approved.
including changes required by the proposed drawing correction filed on, which has been approved by the examiner.
 including changes required by the proposed drawing correction filed on, which has been approved by the examiner. including changes required by the attached Examiner's Amendment/Comment. Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the reverse side of the drawings. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftperson.
including changes required by the proposed drawing correction filed on, which has been approved by the examiner. including changes required by the attached Examiner's Amendment/Comment. Identifying indicia such as the application number (see 37 CER 184(c)) should be written on the system on the system of the system.
 including changes required by the proposed drawing correction filed on
 including changes required by the proposed drawing correction filed on
including changes required by the proposed drawing correction filed on
including changes required by the proposed drawing correction filed on
including changes required by the proposed drawing correction filed on
including changes required by the proposed drawing correction filed on, which has been approved by the examiner. including changes required by the attached Examiner's Amendment/Comment. Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the reverse side of the drawings. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftperson. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Any response to this letter should include, in the upper right hand corner, the APPLICATION NUMBER (SERIES CODE/SERIAL NUMBER). If applicant has received a Notice of Allowance and Issue Fee Due, the ISSUE BATCH NUMBER and DATE of the NOTICE OF ALLOWANCE should also be included. Attachment(s) Notice of References Cited, PTO-892 Information Disclosure Statement(s), PTO-1449, Paper No(s)
including changes required by the proposed drawing correction filed on, which has been approved by the examiner. including changes required by the attached Examiner's Amendment/Comment. Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the reverse side of the drawings. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftperson. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Any response to this letter should include, in the upper right hand corner, the APPLICATION NUMBER (SERIES CODE/SERIAL NUMBER). If applicant has received a Notice of Allowance and Issue Fee Due, the ISSUE BATCH NUMBER and DATE of the NOTICE OF ALLOWANCE should also be included. Attachment(s) Notice of References Cited, PTO-892 Information Disclosure Statement(s), PTO-1449, Paper No(s)
including changes required by the proposed drawing correction filed on, which has been approved by the examiner: including changes required by the attached Examiner's Amendment/Comment. Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the reverse side of the drawings. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftperson. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Any response to this letter should include, in the upper right hand corner, the APPLICATION NUMBER (SERIES CODE/SERIAL NUMBER). If applicant has received a Notice of Allowance and Issue Fee Due, the ISSUE BATCH NUMBER and DATE of the NOTICE OF ALLOWANCE should also be included. Attachment(s) Notice of References Cited, PTO-892 Information Disclosure Statement(s), PTO-1449, Paper No(s)
including changes required by the proposed drawing correction filed on

NOTICE OF ALLOWANCE AND ISSUE FEE DUE

HM12/0830

PATRICK J HAGAN
DANN DORFMAN HERRELL & SKILLMAN
1601 MARKET STREET
SUITE 720
PHILADELPHIA PA 19103-2307

APPLICATION NO.		FILING DATE	TOTAL CLAIMS	EXAMINER AND	DATE MAILED		
	09/011,74	06/22/98	: 035	GUZO, D		1636	08/30/99
First Named Applicant	COLLINS		35	USC 154(b) te	rm ext. =	0 Days	in .

TITLE OF INVENTION FXPRESSION SYSTEMS

ATTY'S DOCKET NO.	CLASS-SUBCLASS	BATCH NO.	APPLN	I. TYPE	SMALL ENTITY	′	FEE DUE	DAT	E DUE
i	435	-006.000	A69	'HTIL	ITY Y	IS	\$605.0	0 1	1/30/9

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED.

THE ISSUE FEE MUST BE PAID WITHIN <u>THREE MONTHS</u> FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. <u>THIS STATUTORY PERIOD CANNOT BE EXTENDED.</u>

HOW TO RESPOND TO THIS NOTICE:

- I. Review the SMALL ENTITY status shown above.

 If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:
 - A. If the status is changed, pay twice the amount of the FEE DUE shown above and notify the Patent and Trademark Office of the change in status, or
 - B. If the status is the same, pay the FEE DUE shown above.

If the SMALL ENTITY is shown as NO:

- A. Pay FEE DUE shown above, or
- B. File verified statement of Small Entity Status before, or with, payment of 1/2 the FEE DUE shown above.
- II. Part B-Issue Fee Transmittal should be completed and returned to the Patent and Trademark Office (PTO) with your ISSUE FEE. Even if the ISSUE FEE has already been paid by charge to deposit account, Part B Issue Fee Transmittal should be completed and returned. If you are charging the ISSUE FEE to your deposit account, section "4b" of Part B-Issue Fee Transmittal should be completed and an extra copy of the form should be submitted.
- III. All communications regarding this application must give application number and batch number.

 Please direct all communications prior to issuance to Box ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PATENT AND TRADEMARK OFFICE COPY

Application/Control Number: 09/011,745

Art Unit: 1636

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Kathleen D. Rigaut on 8/19/99.

2. The application has been amended as follows:

In the Specification:

On Page 11, line 27, insert -Brief Description of the Drawings --

On Page 13, delete lines 12-23 and substitute the following:

-- Figure 6. Fig. 6 shows the nucleic acid sequence of a portion of CeB (SEQ ID NO:2).

Figure 7. Fig. 7 shows the nucleic sequence of a portion of hCMV+intron (SEQ ID NO:3).

Figure 8. Fig. 8 shows the nucleic acid sequence of a portion of hCMV+intronkaSD (SEQ ID NO:4).

Figure 9. Fig. 9 shows the nucleic acid sequence of a portion of FbdelPASAF (SEQ ID NO:5).

Figure 10. Fig. 10 shows the nucleic acid sequence of a portion of FbdelPMOSAF (SEQ ID NO:6).

Figure 11. Fig. 11 shows the nuclei acid sequence of a portion of FbdelPGASAF (SEQ ID NO:7).

A

Art Unit: 1636



Figure 12. Fig. 12 shows the nucleic acid sequence of a portion of FbdelPRDSAF (SEQ ID NO:8).

Figure 13. Fig. 13 shows the nucleic acid sequence of a portion of CMV10A1 (SEQ ID NO:9).

The references cited in the Search Report for PCT/GB96/02061 have been considered, but will not be listed on any patent resulting from this application because they were not provided on a separate list in compliance with 37 CFR 1.98(a)(1). In order to have the references printed on such resulting patent, a separate listing, preferably on a PTO-1449 form, must be filed within ONE MONTH of the mailing date of this communication. NO EXTENSION OF TIME WILL BE GRANTED UNDER EITHER 37 CFR 1.136(a) OR (b) to comply with this requirement.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Guzo whose telephone number is (703) 308-1906. The examiner can normally be reached on Monday-Thursday from 8:00 AM to 5:30 PM. The examiner can also be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, George Elliott, can be reached on (703) 308-4003. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4242 or (703) 305-3014.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

David Guzo August 19, 1999

DAVID GUZO Primary Examiner

80